Fall has always been my favorite season. Unfortunately, San Diego doesn’t quite have the enchanting fall foliage that other places...
A joint initiative between a Singapore-based medical technology company and Duke University is aiming to develop and commercialize artificial intelligence,...
Gradient Denervation Technologies has raised €14 million (around $14.9 million) in funding to support the clinical development and testing of...
An inhaled formulation of imatinib in development by Aerami Therapeutics to treat pulmonary arterial hypertension (PAH), was safe and well...
Did you know? According to the National Institutes of Health, millions of Americans each year selflessly provide unpaid care for...
Treatment with sotatercept in addition to standard pulmonary arterial hypertension (PAH) therapies significantly improved measures of heart health for adults...
Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH). The...
“How are your focus and concentration? Do you need help to stay engaged while reading, writing your columns, or watching...
A Phase 3 clinical trial testing high-dose Opsumit (macitentan) in people with chronic thromboembolic pulmonary hypertension (CTEPH) has ended early...
The protein LTBP1 is active at high levels in pulmonary arterial hypertension (PAH) and may be a diagnostic marker and...
Pulmonary arterial hypertension (PAH) isn’t a one-size-fits-all disease. Each patient’s diagnostic journey and treatment protocol look different, and the condition’s...
AI Therapeutics has begun dosing in a clinical trial testing inhaled LAM-001, a potential disease-modifying therapy for pulmonary arterial hypertension...